TBPH FY 2013 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$685M

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$226,000-99.8% YoY

Gross Profit

-$120M-53253.5% margin

Operating Income

-$156M-69152.2% margin

Net Income

-$156M-69152.2% margin

EPS (Diluted)

$-4.84

Cash Flow

Operating Cash Flow

-$121M

Free Cash Flow

-$124M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$25M

Total Liabilities

$42M

Stockholders' Equity

-$17M

Cash & Equivalents

$0

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$226,000	$130M	-99.8%
Gross Profit	-$120M	$16M	-845.2%
Operating Income	-$156M	-$10M	-1532.2%
Net Income	-$156M	-$10M	-1532.2%